NetScientific shares shot ahead after portfolio company PDS Biotechnology's encouraging update from the ongoing IMMUNOCERV Phase 2 cervical cancer clinical trial.
All nine patients treated with the combination of PDS0101 and CRT had a clinical response with tumour shrinkage greater than 60% at mid-point evaluation, said PDS.
On day 170 of the trial, eight of the nine had no evidence of disease (a complete response), added PDS, which presented the data during a poster session at the 37th Annual Meeting for the Society for Immunotherapy of Cancer.
Frank Bedu-Addo, PDS Biotech's chief executive, said: “Importantly, 100% of patients responded to treatment with the combination of PDS0101 and CRT.
“We believe this study also provides further confirmation that PDS0101 induces the right type, quality, and potency of killer T cells in humans that may translate to effective treatment of cervical cancer. “
"Furthermore, we released expanded interim data from our NCI-led PDS0101-based triple combination trial demonstrating 66% (19/29) survival at median follow-up of 16 months in checkpoint inhibitor refractory HPV-positive cancer patients.
“To date, we have presented PDS0101 Phase 2 efficacy data in over 60 patients and safety data in over 100 patients."
PDS announced the results with its third-quarter results (read more here)
Shares in Netscientific rose 9% to 65p while Nasdaq-listed PDS climbed 27% to US$7.12.